The Treatment of Chronic Amoebic Infection with Metronidazole (Flagyl)

Abstract

After treatment with metronidazole (Flagyl) in daily doses of 1,500 or 2,250 mg for 5 or 10 days, the faeces of 57 from 87 patients (65.5%) with chronic amoebic infection became amoeba-negative and remained so upon repeated follow-up examinations for at least 2 months. Almost all patients with a clinical syndrome of chronic recurrent intestinal amoebiasis reported striking improvement of their abdominal complaints following treatment. Chronic enlargement of the liver, encountered in 30% test subjects, regressed in 7 (from 22) patients only. Flagyl is a very effective direct-acting amoebicide (with rare and mostly mild and transient side effects), acting both against Entamoeba histolytica (EH) as well as against Dientamoeba fragilis (DF). In 11 cases of mixed infection with EH and DF, only DF was found in the 1st or 2nd examination following treatment, but a ‘delayed’ appearance of EH occurred in subsequent stool specimens. If single or short-term treatments (2.0–2.5 g for 1–3 days) which are very effective in acute amoebic dysentery and amoebic liver abscess, should prove to be as efficient also in chronic amoebic infection then Flagyl may be instrumental in eradicating the disease through large-scale mass treatment.

Synthetic Transformations and Medicinal Significance of 1,2,3-Thiadiazoles Derivatives: An Update

“…E. histolytica has infected 40 to 50 million people worldwide and led to the development of amoebic colitis or extraintestinal abscess that has resulted in 100,000 deaths annually [136][137][138]. The tissue amoebiasis is treated by different drugs such as metronidazole, chloroquine, tinidazole, dehydroemetine and nitazoxanide, while the diloxanide furoate and iodoquinoline drugs are used to treat luminal infections (Figure 22) [139][140][141][142][143]. Hayat et al reported the synthetic route to achieve substituted 1,2,3-thiadiazole scaffolds from the cyclization of quinoline-based hydrazone.…”